News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News ESC 2024 New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower Yael L. Maxwell September 04, 2024
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin Yael L. Maxwell March 13, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2020 Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults Shelley Wood November 18, 2020
News Conference News AHA 2019 Early Data Favorable for New RNAi Therapies to Reduce Triglycerides Caitlin E. Cox November 19, 2019
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News SCCT 2019 Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions Yael L. Maxwell July 18, 2019
News Conference News EAS 2019 FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis Michael O'Riordan June 03, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT Michael O'Riordan November 10, 2018
News Conference News ESC 2018 Redefined ‘High-Quality’ Diet Lowers Risk of All-Cause Mortality: PURE Michael O'Riordan August 28, 2018
News Conference News ESC 2018 ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients Todd Neale August 26, 2018
News Conference News EAS 2018 Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction Yael L. Maxwell May 08, 2018